Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fentanyl + melatonin
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutica
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular, Transdermal, Intranasal, Sublingual, Buccal, Intrathecal, Epidural
01
Overview
A combination of fentanyl, a potent opioid analgesic, and melatonin, an endogenous hormone that regulates sleep-wake cycles. Fentanyl is commonly used in anesthesia, for breakthrough cancer pain, or round-the-clock pain management. Melatonin is used for sleep disorders, jet lag, and circadian rhythm disorders.
02
Targets
MTNR1A (MT1)MTNR1B (Melatonin Receptor 2)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on fentanyl + melatonin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fentanyl + melatonin.